UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/785,446	02/23/2004	Lauren Otsuki	NOCAR.007A	1443
	7590 06/06/200 RTENS OLSON & BE	EXAMINER		
2040 MAIN STREET FOURTEENTH FLOOR IRVINE, CA 92614			ROYDS, LESLIE A	
			ART UNIT	PAPER NUMBER
			1614	
			NOTIFICATION DATE	DELIVERY MODE
			06/06/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jcartee@kmob.com eOAPilot@kmob.com



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	1	ATTORNEY DOCKET NO.
10785446	2/23/2004	OTSUKI ET AL.		NOCAR.007A
		EXAMINER		
KNOBBE MARTENS C 2040 MAIN STREET		Leslie A Royds		
FOURTEENTH FLOOR IRVINE, CA 92614			ART UNIT	PAPER
			1614	20080602

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

NOTICE OF NON-RESPONSIVE AMENDMENT

Applicant's response filed March 11, 2008 in response to the requirement for restriction/election dated February 11, 2008 has been received and entered into the present application. However, the reply filed March 11, 2008 is not fully responsive to the previous Office Action(s) because Applicant has failed to provide a structural depiction of the elected adenosine A1 receptor antagonist (AA1RA) KW-3902 as required at page 13 of the Office Action dated February 11, 2008. Applicant is further reminded that, should the elected species of KW-3902 be one of the adenosine A1 receptor antagonist compounds instantly claimed as xanthine-derivative compounds of formula (I) or xanthine epoxide-derivative compounds of formulas (II) or (III), he was additionally required to identify the structural formula [either (I), (II) or (III)] to which the elected species belongs, as well as a clear identification of each and every substituent contained therein that circumscribes the elected specie of adenosine A1 receptor antagonist.

Applicant is advised that a proper response to this reply will reiterate the group and species of cardiovascular disease and beta-blocker elected for examination and clarify the single disclosed species of adenosine A1 receptor antagonist elected for examination on the merits. Note that Applicant is required in reply to this notice to provide a statement of the claims readable on the elected invention, a clear and complete structural depiction of the elected adenosine A1 receptor antagonist compound and, should Applicant elect one of the instantly claimed xanthine-derivative compounds of formula (I) or xanthine epoxide-derivative compounds of formulas (II) or (III) as the species of adenosine A1 receptor antagonist compound for examination on the merits, a clear identification of the generic structural formula to which the elected species belongs [either (I), (II) or (III)] and an identification of each R-group contained within the elected species for examination is also required. Failure to comply with these instructions will again render the reply non-compliant.

Since the above-mentioned response appears to be a bona fide attempt to reply, Applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction, as well as a proper response to the previous Office Action, in order to avoid abandonment. Extensions of this time period under 37 C.F.R. 1.136(a) are available.

Inquiry concerning this communication or earlier communications from the Examiner should be directed to Leslie A. Royds, whose telephone number is (571)-272-6096. The Examiner can normally be reached Monday through Friday, 9:00 AM to 5:30 PM. If attempts to reach the Examiner are unsuccessful, the Examiner's supervisor, Ardin H. Marschel, can be reached on (571)-272-0718. The fax phone number for this organization where this application or proceeding is assigned is (571)-273-8300.

/Ardin Marschel/ Supervisory Patent Examiner, Art Unit 1614 /Leslie A. Royds/ Patent Examiner, Art Unit 1614

PTO-90C (Rev.04-03)